Royalty Report: Drugs, Cancer, Therapeutic – Collection: 67151

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 67151

License Grant
The Board, through the University, hereby grants to Licensee a royalty-bearing, exclusive license under licensed subject matter to the Boards undivided interest in the patent rights and technology rights to manufacture, have manufactured, use, import, offer to sell and/or sell licensed products within licensed territory for use within licensed field.
License Property
New Drug Application with a Phase I / II / III study.  Phase I means the FDA submission and approval process which provides for the first introduction into humans of a product with the purpose of determining human toxicity, metabolism, absorption, elimination and other pharmacological action.  Phase II means the FDA submission and approval process which provides for early controlled clinical studies conducted to obtain preliminary data on the effectiveness of a product for a particular indication.  Phase III means the FDA submission and approval process in which expanded clinical trials are conducted to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of a product.

The Patent and Technology License relates to the WP1122 Portfolio.

WP1122 Portfolio is a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular.

Field of Use
This agreement pertains to the drug industry relating to all fields of use in humans of a product with the purpose of determining human toxicity, metabolism, absorption, elimination and other pharmacological action.

IPSCIO Record ID: 228840

License Grant
The company entered into a license agreement with the nonprofit Licensor covering a new group of molecules recently discovered in connection with research the company have been sponsoring called WP1732, a part of the WP1066 Portfolio.
License Property
The focus is on the development of oncology drug candidates with the following core drug technologies: a uniquely designed anthracycline (Annamycin), a portfolio of STAT3 inhibitors (WP1066 Portfolio) and a collection of inhibitors of glycolysis (WP1122 Portfolio).

WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

WP1732, a new molecule in the WP1066 portfolio.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26488

License Grant
The Licensor grants to the Licensee worldwide rights to Azacitidine, Vidaza.
License Property
Vidaza is the subject of a completed and published Phase III study indicating its safety and efficacy in the treatment of myelodysplastic syndromes, or MDS, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.  The myelodysplastic syndromes are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to acute myelogenous leukemia or AML.
Field of Use
The field of use relates to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.